Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2005 1
2006 1
2007 3
2009 2
2012 1
2013 4
2014 5
2015 1
2016 3
2017 8
2018 2
2019 4
2020 5
2021 7
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Results by year
Filters applied: . Clear all
Page 1
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
Lévy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surénaud M, Lacabaratz C, Perreau M, Foucat E, Déchenaud M, Tisserand P, Blengio F, Hivert B, Gauthier M, Cervantes-Gonzalez M, Bachelet D, Laouénan C, Bouadma L, Timsit JF, Yazdanpanah Y, Pantaleo G, Hocini H, Thiébaut R; French COVID cohort study group. Lévy Y, et al. Among authors: lacabaratz c. iScience. 2021 Jul 23;24(7):102711. doi: 10.1016/j.isci.2021.102711. Epub 2021 Jun 10. iScience. 2021. PMID: 34127958 Free PMC article.
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Bétard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R; EBOVAC2 EBL2001 study group. Pollard AJ, et al. Among authors: lacabaratz c. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217361 Clinical Trial.
Targeting human langerin promotes HIV-1 specific humoral immune responses.
Kervevan J, Bouteau A, Lanza JS, Hammoudi A, Zurawski S, Surenaud M, Dieudonné L, Bonnet M, Lefebvre C, Hocini H, Marlin R, Guguin A, Hersant B, Hermeziu O, Menu E, Lacabaratz C, Lelièvre JD, Zurawski G, Godot V, Henri S, Igyártó BZ, Levy Y, Cardinaud S. Kervevan J, et al. Among authors: lacabaratz c. PLoS Pathog. 2021 Jul 29;17(7):e1009749. doi: 10.1371/journal.ppat.1009749. eCollection 2021 Jul. PLoS Pathog. 2021. PMID: 34324611 Free PMC article.
Durable natural killer cell responses after heterologous two-dose Ebola vaccination.
Wagstaffe HR, Susannini G, Thiébaut R, Richert L, Lévy Y, Bockstal V, Stoop JN, Luhn K, Douoguih M, Riley EM, Lacabaratz C, Goodier MR. Wagstaffe HR, et al. Among authors: lacabaratz c. NPJ Vaccines. 2021 Jan 29;6(1):19. doi: 10.1038/s41541-021-00280-0. NPJ Vaccines. 2021. PMID: 33514756 Free PMC article.
Long-lasting severe immune dysfunction in Ebola virus disease survivors.
Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum BP, Durand M, Krüger M, Keita AK, Ayouba A, Mély S, Fernandez JC, Touré A, Fourati S, Lévy-Marchal C, Raoul H, Delaporte E, Koivogui L, Thiébaut R, Lacabaratz C, Lévy Y; PostEboGui Study Group. Wiedemann A, et al. Among authors: lacabaratz c. Nat Commun. 2020 Jul 24;11(1):3730. doi: 10.1038/s41467-020-17489-7. Nat Commun. 2020. PMID: 32709840 Free PMC article.
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.
Marlin R, Godot V, Cardinaud S, Galhaut M, Coleon S, Zurawski S, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Maisonnasse P, Dupaty L, Fenwick C, Naninck T, Lemaitre J, Gomez-Pacheco M, Kahlaoui N, Contreras V, Relouzat F, Fang RHT, Wang Z, Ellis J 3rd, Chapon C, Centlivre M, Wiedemann A, Lacabaratz C, Surenaud M, Szurgot I, Liljeström P, Planas D, Bruel T, Schwartz O, Werf SV, Pantaleo G, Prague M, Thiébaut R, Zurawski G, Lévy Y, Grand RL. Marlin R, et al. Among authors: lacabaratz c. Nat Commun. 2021 Sep 1;12(1):5215. doi: 10.1038/s41467-021-25382-0. Nat Commun. 2021. PMID: 34471122 Free PMC article.
Prevention of Ebola virus disease through vaccination: where we are in 2018.
Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, Doumbia S, D'Ortenzio E, Lévy-Marchal C, Pierson J, Watson-Jones D, Nguyen VK, Larson H, Lysander J, Lacabaratz C, Thiebaut R, Augier A, Ishola D, Kennedy S, Chêne G, Greenwood B, Neaton J, Yazdanpanah Y. Lévy Y, et al. Among authors: lacabaratz c. Lancet. 2018 Sep 1;392(10149):787-790. doi: 10.1016/S0140-6736(18)31710-0. Epub 2018 Aug 10. Lancet. 2018. PMID: 30104048 Free PMC article. No abstract available.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, Anzala O, Eholie S, Bétard C, Richert L, Lacabaratz C, McElrath MJ, De Rosa S, Cohen KW, Shukarev G, Robinson C, Gaddah A, Heerwegh D, Bockstal V, Luhn K, Leyssen M, Douoguih M, Thiébaut R; EBL2002 Study group. Barry H, et al. Among authors: lacabaratz c. PLoS Med. 2021 Oct 29;18(10):e1003813. doi: 10.1371/journal.pmed.1003813. eCollection 2021 Oct. PLoS Med. 2021. PMID: 34714820 Free PMC article. Clinical Trial.
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, Foucat E, Surenaud M, Guillaumat L, Boilet V, Rieux V, Bouchaud O, Girard PM, Molina JM, Morlat P, Hocqueloux L, Richert L, Pantaleo G, Lelièvre JD, Thiébaut R. Lévy Y, et al. Among authors: lacabaratz c. J Virol. 2021 Apr 12;95(9):e02165-20. doi: 10.1128/JVI.02165-20. Print 2021 Apr 12. J Virol. 2021. PMID: 33568510 Free PMC article. Clinical Trial.
50 results